New research and clinical criteria for Alzheimer’s disease (AD) have recently been proposed, which include biomarker information on Alzheimer’s plaque and tangle pathology, or AD-typical structural brain changes, as supporting or essential elements of an AD diagnosis. 1 , 2 , 3 In a large group of patients with both genetic and cerebrospinal fluid (CSF) biomarker data, we here show that biomarker-assisted diagnosis-making almost doubles the effect size of the association between the ɛ4 variant of the apolipoprotein E ( APOE ) gene and AD.
No takes yet. Share an insight, caveat, or question.
Andréasson et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: